XTalks

JANUARY 29, 2025

Related: Eli Lillys Kisunla (donanemab) Gets Full FDA Approval After Initial Rejection, Gears Up to Take on Leqembi Leqembi was first approved in 2023 as a monoclonal antibody targeting amyloid-beta protofibrils and plaques proteins that cause brain cell damage and cognitive decline in Alzheimers disease.

FDA Approval 66

FDA Approval Sales Antibody Protein 66

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

pharmaphorum

NOVEMBER 5, 2021

Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated with the complement pathway. billion in peak annual sales if it gets approved for all its target indications.

Trials 105

Trials Protein Antibody FDA Approval 105

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S. before expanding it into Europe.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

pharmaphorum

AUGUST 19, 2020

The success of AbbVie’s Humira (adalimumab), which peaked at almost $20 billion in sales in 2018, demonstrates the potential of inflammatory diseases drugs to make mega-bucks.

Antibody 105

Antibody Drugs Protein Sales 105

pharmaphorum

AUGUST 26, 2022

The US biotech claimed conditional marketing approval from the European Commission for Roctavian (valoctocogene roxaparvovec) as a treatment for adults with severe haemophilia A, who don’t have a history of developing the antibodies that inhibit the activity of blood-clotting protein Factor VIII.

Gene Therapy 111

Gene Therapy Gene Antibody Marketing 111

pharmaphorum

OCTOBER 21, 2022

The acquisition of DJS Antibodies, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins – such as G protein-coupled receptors (GPCRs) – will extend AbbVie’s present discovery research capabilities, through DJS’ proprietary HEPTAD platform.

Antibody 59

Antibody Protein Research Medicine 59

pharmaphorum

MARCH 9, 2022

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, so the two companies are hoping a new long-acting drug candidate can revitalise the franchise. The half life of the new drug – one of the main draws for Sanofi’s $11.6

Protein 98

Protein Gene Therapy Sales Regulation 98

XTalks

FEBRUARY 26, 2024

Xolair is a monoclonal antibody that binds to IgE, a type of antibody in the body that triggers allergic reactions, to block it from binding to its receptors. billion in sales last year. Xolair is the first medication approved by the FDA to reduce allergic reactions to more than one type of food after accidental exposure.

Allergies 100

Allergies FDA Approval Drugs Protein 100

Delveinsight

OCTOBER 1, 2021

This disease is associated with antibodies directed against the acetylcholine receptor, muscle-specific kinase (MUSK), lipoprotein-related protein 4 (LRP4), or agrin in the postsynaptic membrane at the neuromuscular junction. The latter are Anti-Acetylcholine Receptor (AChR) antibody-positive. Soliris (Eculizumab).

Marketing 85

Marketing Antibody Drugs Sales 85

pharmaphorum

AUGUST 27, 2021

Incyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for patients with certain types of lymphoma. Both Yescarta and Kymriah are already on sales in the EU, while Breyanzi is under regulatory review.

Antibody 72

Antibody Sales Protein Marketing 72

Pharmaceutical Technology

FEBRUARY 24, 2023

antibody-drug conjugate (ADC), CMG901. monoclonal antibody, a cytotoxic small molecule monomethyl auristatin E (MMAE) and a protease-degradable linker. cell surface protein, including gastric cancers. AstraZeneca has signed a global exclusive licence agreement with KYM Biosciences for the latter’s Claudin-18.2

Antibody 130

Antibody Development Engineer Clinical Trials 130

pharmaphorum

JUNE 9, 2022

mRNA-1273.214 stimulated almost twice the neutralising antibody levels against the Omicron strain than Spikevax , with a significantly higher response also seen against other variants of concern, one month after administration, according to the company. It has predicted sales of COVID-19 vaccines will be around $21 billion this year.

Vaccine 105

Vaccine Vaccination Containment Clinical Trials 105

pharmaphorum

FEBRUARY 9, 2022

Closely related to this is the fact that global spending on oncology drugs reached $164 billion in 2020, with drug sales growing at a compound annual growth rate of 14.3% While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response.

Vaccine 134

Vaccine Vaccination Clinical Trials Clinical Trials 134

pharmaphorum

MARCH 31, 2021

The diagnostic imaging agents all target fibroblast activation protein (FAP), a molecule that is only expressed at low levels on healthy cells but is found much more abundantly in solid tumours. billion or more in peak sales. “We believe this technology has the potential to transform many patients’ lives,” she added. .

Licensing 98

Licensing Licensing Gene Therapy Sales 98

pharmaphorum

NOVEMBER 16, 2021

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. In another 14-day trial involving men and women, MK-0616 reduced LDL cholesterol by around 65% from baseline when it was added to background therapy with statins.

Trials 98

Trials Drugs Sales Clinical Trials 98

pharmaphorum

SEPTEMBER 2, 2020

The drug, JTX-1811, is a monoclonal antibody designed to selectively deplete immunosuppressive tumour-infiltrating T regulatory (TITR) cells. . When JTX-1811 binds to CCR8, it targets TITR cells for depletion by an enhanced antibody-dependent cellular cytotoxicity mechanism. .

Licensing 72

Licensing Licensing Antibody Immune Response 72

XTalks

JUNE 30, 2023

Hemophilia A is a rare genetic bleeding disorder that is caused by a mutation in the gene that encodes the key blood clotting protein factor VIII (FVIII). Severe hemophilia A is usually treated with FVIII replacement therapy or an antibody-based drug to improve the ability of blood to clot and reduce the likelihood of bleeding.

Gene Therapy 98

Gene Therapy Gene FDA Approval Antibody 98

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. If it proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will distribute and record sales for REGN-COV2 in the U.S. and around the world.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

XTalks

NOVEMBER 1, 2024

In this blog, we highlight the top 20 best-selling neurology drugs to watch in 2024, based on 2023 sales statistics. We discuss each drug’s approved uses, sales performance and why they’ve become essential in the neurology space. Related: Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data 1. billion in the US and $4.1

FDA Approval 85

FDA Approval Drugs Botox Sales 85

The Pharma Data

APRIL 12, 2023

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Biogen Inc. Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ).

Antibody 40

Antibody Development Engineer Licensing 40

pharmaphorum

APRIL 29, 2021

IgAN is a rare autoimmune condition, sometimes called Berger’s disease, in which antibodies accumulate in the kidney, causing inflammation and scarring that can develop into chronic kidney disease (CKD). The post FDA sets September review date for Calliditas’ rare kidney disease drug appeared first on.

Drugs 91

Drugs Marketing Trials Clinical Trials 91

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

pharmaphorum

SEPTEMBER 14, 2020

US-based Merck, known as MSD outside North America, will globally develop and market Seattle’s investigational antibody-drug conjugate (ladiratuzumab vedotin). The drug zeroes in on cancer cells expressing a protein known as LIV-1 and is in phase 1 development for breast cancer and other solid tumours.

Genetics 52

Genetics Development Drugs Protein 52

Delveinsight

JULY 29, 2021

billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibody technologies focused on cancer and other disease targets. An antisense treatment, BIIB080 potentially aims at microtubule-linked protein tau (MAPT) messenger RNA (mRNA) and impedes tau protein production.

Drugs 98

Drugs Protein Life Science Development 98

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. Shape’s RNA editing technology could potentially modify the amount of a key regulatory protein in the body or treat genetic diseases. BlueWillow shared little data about how the vaccine performed in its interim analysis.

Vaccine 98

Vaccine Vaccination Gene Therapy RNA 98

The Pharma Data

AUGUST 10, 2020

All revenue from sales of the vaccine in the regions covered by the deal will be split between Novavax and SIIPL, after agreed deductions. The candidate is built upon a stable, prefusion protein and includes Novavax’s Matrix?M M adjuvant.

Vaccine 52

Vaccine Vaccination Licensing Licensing 52

pharmaphorum

MARCH 30, 2022

When the first generation vaccine CVnCoV failed its phase 2b/3 test last summer, the writing looked to be on the wall for the alliance, with multiple COVID-19 shots already available with more coming down the pipeline – including GSK and Sanofi’s recombinant protein candidate – and prospects looking slim in an increasingly crowded market.

Vaccine 64

Vaccine Vaccination Protein Antibody 64

Pharmaceutical Technology

MAY 15, 2023

LM-305 is a new pre-clinical stage antibody-drug conjugate (ADC) that targets G protein-coupled receptor, class C, group 5, member D (GPRC5D). It comprises an anti-GPRC5D monoclonal antibody, a cytotoxic payload monomethyl auristatin E (MMAE) and a protease-degradable linker.

Medicine 130

Medicine Antibody Development Drugs 130

pharmaphorum

AUGUST 16, 2020

The fund has already been deployed to order Gilead’s antiviral drug Veklury (remdesivir) and apheresis equipment to collect antibodies from the blood of patients who have recovered from COVID-19.

Vaccine 111

Vaccine Vaccination Immune Response Trials 111

pharmaphorum

JANUARY 18, 2021

J&J’s Janssen pharma unit got approval for Darzalex Faspro as a multiple myeloma treatment in the US last May and in Europe the following month, lending further momentum to a franchise that looks set to make more than $4 billion in sales in calendar 2020.

Drugs 98

Drugs Licensing Licensing Production 98

pharmaphorum

MAY 31, 2022

billion in sales last year. The pandemic and the timing of US government purchases for immunisation campaigns trimmed back sales from almost $5.9 The vaccine is based on Affinivax’ multiple antigen presenting system, or MAPS, which combines polysaccharide and protein antigens joined with a biotin-rhizavidin bond.

Vaccine 52

Vaccine Vaccination Bacterium Sales 52

pharmaphorum

DECEMBER 22, 2020

million on the table if certain development, regulatory and sales goals are achieved. These followed two deals late last week – on Thursday GSK made an $85 million licensing agreement with Surface Oncology for an early-stage antibody asset, which adds a natural killer cell approach to the company’s oncology portfolio.

Licensing 52

Licensing Licensing Genetics Sales 52

pharmaphorum

FEBRUARY 28, 2022

Biocon’s partnership with Mylan – which merged with Pfizer’s Upjohn to form Viatris in 2020 – dates back more than a decade and has generated a number of biosimilars including insulin analogues, antibodies and recombinant proteins.

Insulin 102

Insulin Production Marketing Engineer 102

pharmaphorum

AUGUST 31, 2022

BIVV001 is a Factor VIII replacement therapy that is being developed as a successor to Eloctate (efmoroctocog alfa), Sanofi and Sobi’s current Factor VIII drug that is dosed every four days and has seen its sales decline in an increasingly competitive market. The drug was one of the primary drivers for Sanofi’s $11.6

Drugs 52

Drugs Protein Marketing Gene Therapy 52

pharmaphorum

AUGUST 17, 2020

With Massachusetts-based Dragonfly BMS is taking a different tack and focusing on DF6002, a long-lasting fusion protein that looks like the “tail” (Fc) end of an IL-12 antibody. The companies hope that this will cause the area around the tumour to become inflammatory and begin to work against it.

Gene Therapy 59

Gene Therapy Clinical Trials Clinical Trials Gene 59

The Pharma Data

DECEMBER 5, 2020

(NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells.

Antibody 40

Antibody Production Trials Medicine 40